Enliven Therapeutics, Inc.
ELVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. With a market capitalization of $2.41B, it sits in mid-cap territory. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Market Cap
$2.41B
Beta
0.45
P/E (TTM)
—
P/E (Fwd)
-16.60
EPS (TTM)
$-1.64
EPS (Fwd)
$-2.38
ROE
-26.6%
ROA
-18.9%
Cash
$452.4M
Total Debt
$302,000
Free CF
-$46.1M
52W Change
106.7%
Annual Financials
Cash vs Debt
With $452.4M in cash and $302K in debt, ELVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$46.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Enliven Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Enliven Therapeutics, Inc.'s trajectory.